Pharmacopeia
Andexanet alfa
Core pharmacology
- Class Group
Modified recombinant factor Xa decoy protein; direct factor Xa inhibitor reversal agent.
- Main Action
Rapidly reduces anticoagulant activity of direct factor Xa inhibitors by binding/sequestering them.
- Mechanism of action
Modified recombinant human factor Xa retains affinity for factor Xa inhibitors but lacks normal factor Xa catalytic procoagulant function. It also interacts with tissue-factor-pathway inhibitor.
- Indications Uses
Historically provisionally authorised in Australia for reversal of apixaban/rivaroxaban in adults with life-threatening or uncontrolled bleeding; NOT currently ARTG-registered. Retained here for pharmacology/exam study.
- Adverse Effects Toxicity
Thrombotic and ischaemic events, including stroke and myocardial infarction, are major safety concerns; infusion-related and other adverse reactions may occur. Clinical outcome benefit is uncertain.
- Special Points
AUSTRALIA: provisional registration of ANDEXXA lapsed 20 May 2026; the product was removed from the ARTG. The NSW Medicines Formulary does not list andexanet alfa. Do not present this as routinely available for Australian ICU use; seek current local haematology/transfusion guidance for management of factor Xa inhibitor-related bleeding.
Source references
These October 2026 additions were reconciled against the linked sources. Refer to current local formulary guidance for clinical prescribing.